MilliporeSigma and Erbi Logos

MilliporeSigma Acquires Erbi Biosystems

MilliporeSigma and Erbi Logos

The acquisition expands MilliporeSigma’s portfolio to a full range of bioreactors, from 2ml to 2000L, and adds to the company’s expertise in monoclonal antibody (mAb) process development.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, has acquired Massachusetts-based Erbi Biosystems, developer of the Breez 2 ml micro-bioreactor platform technology. The deal expands Millipore Sigma’s portfolio in therapeutic proteins by enabling scalable cell-based perfusion bioreactor processes from 2ml to 2000L. The Breez was designed for rapid bioprocessing and cell therapy development, resulting in the potential for lower manufacturing costs and increased speed to market.

“Erbi’s Breez is one of the few micro-scale, fully automated, functionally closed and continuous perfusion cell culture platform technologies on the market. Its footprint is also much smaller than that of other bioreactor platform technologies,” said Darren Verlenden, Head of Process Solutions, Life Science business sector of Merck KGaA. “By integrating the Breez in our extensive Mobius portfolio, we can now offer a full range of bioreactors, cell retention systems and devices, and cell culture media. This increases the productivity of our upstream processes and will further accelerate the adoption of perfusion cell culture operations as our customers move towards more connected and continuous processing.”

“We look forward to joining the Life Science business sector of Merck KGaA, Darmstadt, Germany and are confident that our expertise in bioprocessing process development will complement the Mobius portfolio and help advance life-enhancing therapeutics,” said Michael Chiu, President and CEO at Erbi Biosystems.


Related Articles